Unveiling molecular insights: in silico exploration of TLR4 antagonist for management of dry eye syndrome
Background Dry eye disease is the most commonplace multifractional ocular complication, which has already affected millions of people in the world. It is identified by the excessive buildup of reactive oxygen species, leading to substantial corneal epithelial cell demise and ocular surface inflammat...
Saved in:
Main Authors: | Kothandan Sudhakar, Neeru Dugar, Srikanth Jupudi, Ravichandran Ashwin, Kuppusamy Gowthamarajan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-05-01
|
Series: | BMJ Open Ophthalmology |
Online Access: | https://bmjophth.bmj.com/content/9/1/e001610.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation
by: Agata Habas, et al.
Published: (2022-01-01) -
Eyes Open on Sleep and Wake: In Vivo to In Silico Neural Networks
by: Amaury Vanvinckenroye, et al.
Published: (2016-01-01) -
Photoreceptor metabolic window unveils eye–body interactions
by: Shaopeng Yang, et al.
Published: (2025-01-01) -
Aging: A Predisposition to Dry Eyes
by: Anushree Sharma, et al.
Published: (2014-01-01) -
Dry Eye Disease and Refractive Corrections
by: David Madrid-Costa, et al.
Published: (2019-01-01)